key: cord-0981303-1misd9lu
authors: Al-Hatmi, Abdullah M.S.; Mohsin, Jalila; Al-Huraizi, Aisha; Khamis, Faryal
title: COVID-19 associated invasive candidiasis
date: 2020-08-07
journal: J Infect
DOI: 10.1016/j.jinf.2020.08.005
sha: 81775700485d73c91d80aa2e3abf24efdb483d21
doc_id: 981303
cord_uid: 1misd9lu

nan

To the Editor: We have read with special interest the excellent review by Louise Lansbury and colleagues 1 , 'Co-infections in people with COVID-19: a systematic review and meta-analysis'. In this review, four fungal pathogens were reported from three studies [2] [3] [4] , namely Candida albicans, Candida glabrata, Aspergillus flavus and Aspergillus fumigatus. In addition, Hughes et al. 5 However, his inflammatory markers started rising again and a repeat peripheral blood culture grew C.

albicans and was given caspofungin.

Despite progress in public health and hospital care, infections continue to develop in hospitalised patients with COVID-19. COVID-19 patients in ICU, are at high risk of developing nosocomial infections associated with MV and respiratory manifestation. 7 Medical procedures and invasive techniques are considered as potential routes of bacterial and fungal infections which are common complications of viral pneumonia. 8 Invasive candidiasis is rare but associated with considerable mortality in critically ill patients. 9 The main risk factors for our invasive candidemia patients are; prolong hospital stays, CVC, surgical procedure and the use of broad-spectrum antibiotics (Table1). All our 5 patients were diagnosed as invasive candidiasis by the positive blood culture. Three Candida species were identified; C. albicans, C. galabrata and C. tropicalis using Maldi-tof and susceptibility results shown in Table 2 . All patients underwent CVC removal.

Persistent candidemia occurred in one patient despite CVC removal and appropriate antifungal therapy. Four patients received antifungal therapy; two received caspofungin alone, two received combination of (caspofungin + amphotericin B) and (voriconazole + caspofungin) and one patient did not receive any antifungals. Despite antifungal therapy, 3 out of 5 patients died. Our observations suggest increased risk for critically ill COVID-19 patients to develop co-infection with Candida, which is likely to increase mortality rates. Considering the high mortality, the need for early recognition of candidemia and appropriate antifungal therapy are basic requirements to improve the outcome of COVID-19 patients in ICU. With this report, we aim to call attention of clinicians to recognize the nosocomial infections associated with COVID-19 patients.

This research received no external funding

The authors declare no conflict of interest 

Co-infections in people with COVID-19: a systematic review and meta-analysis

Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Diagnosing COVID-19-associated pulmonary aspergillosis

Co-infections: potentially lethal and unexplored in COVID-19

Opportunistic bacterial, viral and fungal infections of the lung

Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy